Increase of antigen production in BLV-infected cell lines via additional expression of tax. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Increase of antigen production in BLV-infected cell lines via additional expression of tax.

Zentralbl Veterinarmed [B]. 1995 Nov;42(9):543-50. Unique Identifier : AIDSLINE MED/96092126
Wagner HJ; Blankenstein P; Bondzio A; Ebner D; Risse S; Free University Berlin, Department of Veterinary Medicine,; Germany.

Abstract: The selection of animals infected with the bovine leukaemia virus (BLV) is performed by the immunological detection of antibodies against the virus, commonly using the antigen gp51. Furthermore, research is being carried out to develop protective vaccines against BLV that have gp51 as their main component. Taking both of these factors into account, it is clear that there will be an increasing requirement for the virus antigen gp51 for some time to come. The permanently BLV-infected foetal lamb kidney cell line FLK/BLV (and its sublines) has been proved to be the most useful culture for the mass production of the virus antigen. Stable cell lines producing higher quantities of BLV antigen have not been established, either by subcloning of the FLK/BLV or by infection of other permanent cells with BLV. Here, a report is made on efforts to increase the expression of gp51 in BLV-infected cells via the additional expression of homologous transactivating virus protein tax. Selectable tax expression vectors that integrate into the host cell genome were constructed using BL provirus DNA fragments. Highly productive FLK/BLV cells were transfected with these vectors. Following selection with G 418, gp51-producing cell lines were established and tested for their productivity for several months. Some tax-vector-containing cell lines have produced 1.5-2 times more gp51 than the highly productive parental control cell line FLK/BLV 44-1.
Keywords: Animal Antigens, Viral/*BIOSYNTHESIS/GENETICS Cell Line Cercopithecus aethiops Cryopreservation Gene Expression Regulation, Viral Gene Products, tax/*BIOSYNTHESIS/GENETICS Genes, pX Leukemia Virus, Bovine/GENETICS/*IMMUNOLOGY/METABOLISM Sheep Support, Non-U.S. Gov't Vero Cells JOURNAL ARTICLE

KWDanimalantigens,viral/KWDbiosynthesis/geneticscelllinecercopithecusaethiopscryopreservationgeneexpressionregulation,viralgeneproducts,tax/KWDbiosynthesis/geneticsgenes,pxleukemiavirus,bovine/genetics/KWDimmunology/metabolismsheepsupport,non-uKWDsKWDgov'tverocellsjournalarticle
960630
M9660741

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .